News & Updates

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are at greater risk of developing incident hepatocellular carcinoma (HCC) when factors such as smoking, alcohol use, obesity, diabetes, and hypertension are present, according to a study. However, use of statin, metformin, or aspirin may modify disease progression.

Use of an SGLT-2 inhibitor, compared with a GLP-1 receptor agonist or a DPP-4 inhibitor, helps to prevent nephrolithiasis from recurring in patients with type 2 diabetes (T2D) and pre-existing nephrolithiasis or gout, as shown in target trial emulation studies.